Antibody Drug Targets and Focus on Breast- & Prostate Cancer

Table of Contents

1. Executive Summary

2. Methodologies

3. Table of Contents

• 3.1 List of Figures
• 3.2 List of Tables
• 3.3 List of Boxes

4. Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?

5. Antibody Drug Targets by Molecular Function

• 5.1 Carboxypeptidase Activity Targets
• 5.2 Catalytic Activity Targets
• 5.3 Cell Adhesion Molecule Activity Targets
• 5.4 Chaperone Activity Targets
• 5.5 Chemokine Activity Targets
• 5.6 Cofactor Binding Targets
• 5.7 Complement Activity Targets
• 5.8 Cytokine Activity Targets
• 5.9 DNA Topoisomerase Activity Targets
• 5.10 Extracellular Matrix Structural Constituent Targets
• 5.11 G-protein Coupled Receptor Activity Targets
• 5.12 Growth Factor Activity Targets
• 5.13 Hormone Activity Targets
• 5.14 Hydrolase Activity Targets
• 5.15 Intracellular Ligand-gated Ion Channel Activity Targets
• 5.16 Metallopeptidase Activity Targets
• 5.17 MHC Class I Receptor Activity Targets
• 5.18 Molecular Function Unknown Targets
• 5.19 Oxidoreductase Activity Targets
• 5.20 Peptide Hormone Targets
• 5.21 Protease Inhibitor Activity Targets
• 5.22 Protein Binding Targets
• 5.23 Receptor Activity Targets
• 5.24 Receptor Binding Targets
• 5.25 Receptor Signaling Complex Scaffold Activity Targets
• 5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
• 5.27 RNA-directed DNA polymerase Activity Targets
• 5.28 Serine-type Peptidase Activity Targets
• 5.29 T Cell Receptor Activity Targets
• 5.30 Translation Regulator Activity Targets
• 5.31 Transmembrane Receptor Activity Targets
• 5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
• 5.33 Transporter Activity Targets
• 5.34 Unclassified Targets

6. Antibody Drugs Targeting Signaling Pathways

• 6.1 Alpha6 Beta4 Integrin Signaling Pathway
  • 6.1.1 Description of Pathway
  • 6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.2 Androgen Receptor Signaling Pathway
  • 6.2.1 Description of Pathway
  • 6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.3 B Cell Receptor Signaling Pathway
  • 6.3.1 Description of Pathway
  • 6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
• 6.4 EGFR1 Signaling Pathway
  • 6.4.1 Description of Pathway
  • 6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.5 IL-2 Signaling Pathway
  • 6.5.1 Description of Pathway
  • 6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
• 6.6 IL-4 Signaling Pathway
  • 6.6.1 Description of Pathway
  • 6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
• 6.7 IL-6 Signaling Pathway
  • 6.7.1 Description of Pathway
  • 6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.8 Kit Receptor Signaling Pathway
  • 6.8.1 Description of Pathway
  • 6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.9 Notch Signaling Pathway
  • 6.9.1 Description of Pathway
  • 6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.10 T Cell Receptor Signaling Pathway
  • 6.10.1 Description of Pathway
  • 6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.11 TGF-beta Receptor Signaling Pathway
  • 6.11.1 Description of Pathway
  • 6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type
• 6.12 TNF-alpha Signaling Pathway
  • 6.12.1 Description of Pathway
  • 6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.13 Wnt Signaling Pathway
  • 6.13.1 Description of Pathway
  • 6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

7.Antibodies Targeting Cancer Stem Cells

8.Targets of Antibody Conjugates

9.Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects

• 9.1 Anti-Angiogenesis
• 9.2 Apoptosis
• 9.3 Protein Kinase Inhibitors

10. Antibody Targets and Drugs by Cancer Indications

• 10.1 Basal Cell Cancer
• 10.2 Biliary Cancer
• 10.3 Bladder Cancer
• 10.4 Bone Cancer
• 10.5 Brain Cancer
• 10.6 Breast Cancer
• 10.7 Cervical Cancer
• 10.8 Cervical Dysplasia
• 10.9 Colorectal Cancer
• 10.10 Endometrial Cancer
• 10.11 Esophageal Cancer
• 10.12 Fallopian Tube Cancer
• 10.13 Gastrointestinal Cancers
• 10.14 Head and Neck Cancer
• 10.15 Leukemias
• 10.16 Liver Cancer
• 10.17 Lung Cancers
• 10.18 Lymphomas
• 10.19 Melanoma
• 10.20 Mesothelioma
• 10.21 Myelodysplastic syndrome
• 10.22 Myelomas
• 10.23 Nasopharyngeal Cancer
• 10.24 Oesophageal Cancer
• 10.25 Ovarian Cancer
• 10.26 Pancreatic Cancer
• 10.27 Peritoneal Cancer
• 10.28 Prostate Cancer
• 10.29 Renal Cancers
• 10.30 Sarcomas
• 10.31 Thyroid Cancer

11. Expression Profiles of Antibody Drug Targets

• 11.1 Human Tissues and Cancer Tissues
• 11.2 Cancer Lines and Cells

12. Breast Cancer: An Introduction

• 12.1 Disease Definitions
• 12.2 Etiology
• 12.3 Epidemiology
• 12.4 Prognosis

13. Current Treatment Strategies of Breast cancer

• 13.1 Localized Disease
• 13.2 Advanced Disease

14. Progress in Current Breast Cancer Treatment Strategies

• 14.1 Hormone Based Therapies
• 14.2 Antibodies
• 14.3 Chemotherapy
• 14.4 Chemotherapy

15. Key Therapeutic Strategies for Future Breast Cancer Therapies

• 15.1 Therapeutic Type, Targets & Mechanisms

16. Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline

• 16.1 The Epothilones
• 16.2 Cell Cycle & Apoptosis
• 16.3 Protein Kinase Inhibitors
• 16.4 Immunotherapy

17. Current Drug Development for Breast Cancer: The Early Stage Pipeline

• 17.1 DNA Targeting
• 17.2 FTIs
• 17.3 Antisense
• 17.4 New Hormone Modulators
• 17.5 Other

18 Prostate Cancer: An Introduction

• 18.1 Disease Definitions
• 18.2 Etiology & Pathophysiology
• 18.3 Epidemiology
• 18.4 Prognosis

19. Current Prostate Cancer Treatment Strategies

• 19.1 Localized Disease
• 19.1.1 Locally Advanced Prostate Cancer
• 19.2 Metastatic Prostate Cancer
  • 19.2.1 Hormone-Sensitive Metastatic Prostate Cancer
  • 19.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer

20. Progress in Current Prostate CancerTreatment Strategies

• 20.1 Long-Term Follow-up Data not yet Been Published
• 20.2 Significant Reduced Risk of Distant Metastases
• 20.3 Adverse Events
• 20.4 No Difference in Overall Survival
• 20.5 Cross-over Design an Optimal Option?
• 20.6 Death due to Liver Failure
• 20.7 Survival Benefit
• 20.8 Subdermal Implant
• 20.9 No FDA Approval
• 20.10 No Improvement in 5-year Disease-Free Survival
• 20.11 Effective Secondary Hormonal Therapy?
• 20.12 Synery in Combination

21. Key Therapeutic Strategies for Future Prostate Cancer Therapies

• 21.1 Therapeutic Type, Targets & Mechanisms

22. Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline

• 22.1 Reduced Prostate Cancer Risk
• 22.2 High Activity in Metastatic AIPC Patients
• 22.3 Absence of Severe Toxicities
• 22.4 Waiting for Data
• 22.5 Probability of Regulatory Approval?
• 22.6 Co-development and License Agreement
• 22.7 Improves Predicted Survival?
• 22.8 Slow Progress & Development Partners
• 22.9 Exclusive License Agreement

23. Current Prostate Cancer Drug Development: The Early Stage Pipeline

• 23.1 New Data?
• 23.2 Terminated Study
• 23.3 More Than 50% PSA decline
• 23.4 Safety and Tolerability
• 23.5 Terminated?
• 23.6 Marker of Drug Effect
• 23.7 Preliminary Results for a Tyrosine Kinase Inhibitor
• 23.8 No Activity in Monotherapy
• 23.9 Dramatic Disappearance of Bone Metastatic Lesions
• 23.10 PSA Response - Anthracycline

24. Disclaimer

25. Drug Index

26. Company Index

27. Appendix I: Antibody Targets by Companies